Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.38 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.37 |
| ▸ | OGT | O15294 | 1/20 | 0.36 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4985659 | 0.88 | MEN1 (0.42) | MEN1KMT2AOGTMEP1BSMN1; SMN2 | |
| SCHEMBL5664866 | 0.87 | KLKB1 (0.40) | MEN1KMT2AKLKB1MAP4K1NOD2 | |
| SCHEMBL4986144 | 0.80 | MEN1 (0.40) | MEN1KMT2AGAASMN1; SMN2KDM4E | |
| SCHEMBL13993523 | 0.73 | MTTP (0.62) | — | |
| SCHEMBL5666297 | 0.73 | KLKB1 (0.37) | MEN1KMT2AKLKB1MAP4K1KDM4E | |
| SCHEMBL20921201 | 0.71 | MEN1 (0.46) | MEN1KMT2AGAAKLKB1MAP4K1 | |
| SCHEMBL5666773 | 0.71 | MTTP (0.53) | — | |
| SCHEMBL4986155 | 0.67 | PLAU (0.40) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12800156 | 0.66 | KLKB1 (0.43) | MEN1KMT2AGAAKLKB1MAP4K1 | |
| SCHEMBL22393977 | 0.65 | SCN10A (0.43) | GAAKLKB1MAP4K1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468378-B2 | Substituted quinoline compounds | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7393958-B2 | Triamide-substituted heterobicyclic compounds | PFIZER, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7368573-B2 | Triamide-substituted heterobicyclic compounds | PFIZER INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2007-04-26 | — | — | US | disclosed |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | BERTINATO PETER | 2006-10-05 | — | — | US | disclosed |
| US-20050234099-A1 | Substituted quinoline compounds | PFIZER INC | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234099-A1 | Substituted quinoline compounds | APOB, APOL1, MTPN | MEN1 1437/4885KMT2A 3968/4885GAA 579/4885 |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | APOB, MTPN, CTRB1 | MEN1 1637/4885KMT2A 4384/4885GAA 671/4885 |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | APOB, MTPN, CTRB1 | MEN1 1637/4885KMT2A 4384/4885GAA 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.